Bristol Myers’ Opdivo with Exelixis drug cuts kidney cancer death risk: study NEW YORK (Reuters) – Bristol Myers Squibb Co’s cancer immunotherapy Opdivo in combination with Exelixis Inc’s Cabometyx reduced […]
A Phase III trial is planned after promising results were revealed from Dana-Farber Cancer Institute for MK-6482 in advanced clear cell kidney cancer.
New clinical data shows that Eli Lilly’s investigational oncology drug pegilodecakin, in combination with a checkpoint inhibitor, could be a potential new treatment for patients with non-small cell lung cancer and kidney cancer.
U.S. drugmaker Merck & Co. Inc. agreed to buy Peloton Therapeutics Inc. for $1.05 billion in cash, gaining access to the privately held company’s lead kidney cancer drug candidate.
The Food and Drug Administration approved Merck & Co.’s cancer therapy Keytruda as part of a combination therapy for previously untreated patients with the most common type of kidney cancer.
2017 Annual Report – Top 200 Medicines: Humira Remains Atop The Throne
Analysts, August 2017, Autoimmune Diseases, Autoimmune Disorders, Biologics, Biosimilars, Blockbusters, Blood Cancers, Breast Cancer, Cervical Cancer, Colorectal Cancer, Forecasts, Forecasts, Gastroenterology, Hepatitis C, Immunology, Inflammatory Diseases, Japan, Kidney Cancer, Mantle Cell Lymphoma (MCL), Multiple Myeloma, Ovarian Cancer, Pneumococcal Disease, Pneumonia, Relapsed Glioblastoma, Rheumatoid Arthritis, Rheumatology, Special Reports, Therapeutics, Top 200 Medicines, Tumor Necrosis Factor (TNF) Inhibitors, Ulcerative Colitis, Vaccines, VasculitisAbbVie’s biologic therapy Humira for autoimmune disorders continues to dominate the sales landscape; Gilead’s once-daily hepatitis C treatment Harvoni in 2016 repeated its performance as the world’s second-best-selling prescription medicine.
2016 Annual Report: Top 200 Medicines
Angiogenesis, August 2016, Autoimmune Diseases, Autoimmune Disorders, Biologics, Biosimilars, Breast Cancer, Cervical Cancer, Colorectal Cancer, Crohn's Disease, Diabetes, FDA, FDA/Regulatory, Hepatitis C, Inflammatory Diseases, Kidney Cancer, Launches, Lung Cancer, Monoclonal Antibodies, Oncology, Ovarian Cancer, Patents, Plaque Psoriasis, Product Launches, Psoriasis, Rheumatoid Arthritis, Sales, Special Reports, Therapeutics, Ulcerative ColitisAbbVie’s biologic therapy Humira for autoimmune diseases was the worldwide prescription-drug sales leader in 2015 for the fourth consecutive calendar term.
Update: This morning, Bristol-Myers Squibb announced that its immunotherapy, Opdivo, also delayed cancer progression more than Afinitor in kidney cancer. This raises questions about the sales potential of Exelixis’ drug. […]